GSK Collaborates With Angiochem to Develop LSDs Medication
As per recent reports, it has been revealed that GSK has entered into a deal with Angiochem in which both the organizations will be working together to develop treatments for Lysosomal Storage Diseases (LSDs). Company officials are of the view that both the organizations are master in their fields, which will help them discover treatment for the disease.
If the pair will be able to develop the medicine then they will be get more than $300 million. Industry experts said that Angiochem will use its rich knowledge of creating novel therapeutic treatments, while GSK will apply its commercialization capability to create medicines for the rare disease.
Drugs are available to treat the problem, but they are not able to restore enzyme function in the Central Nervous System (CNS), which is necessary to derive best results of the medicine. The main aim of Angiochem will be to prepare a drug, which penetrates in the CNS and brings a decline in the symptoms of LSDs.
Lysosomal storage diseases is quite a rare disease, which affects one in 1, 00,000 people. It generally affects children who mostly die at young age or after a few months of the detection of the disease. LSD is not a single disease, but a group of diseases such as Tay Sachs Disease, Fabry Disease, Gaucher's Disease, Pompe Disease and Hunter syndrome.
"”Our collaboration with GSK reflects our belief in the need to effectively address neurological symptoms of lysosomal storage diseases. We are pleased to collaborate with GSK, a committed leader in this rare disease area”, said Jean-Paul Castaigne, who is the President and CEO of Angiochem. Jean further affirmed that the development of the drug will increase their resources as well in the field of EPiC-enzymes.
Prominent Socialist Party leader Bertrand Delanoe...Read More
Presidential election candidate Emmanuel Macron has...Read More
Many personal care products available in the market...Read More
Centre-right Republican leaders will meet today to...Read More
Researchers at MIT have published a new research...Read More